News

Filter

Current filters:

TarcevaIressa

1 to 9 of 31 results

UK’s NICE consults on updating guidance for Tarceva and Iressa

UK’s NICE consults on updating guidance for Tarceva and Iressa

04-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) said this morning that it is reviewing…

AstraZenecadocetaxelIressaOncologyPharmaceuticalRegulationRocheTarcevaUK

Lung cancer treatment takes another forward step in New Zealand

Lung cancer treatment takes another forward step in New Zealand

09-01-2014

Improvements in lung cancer treatment are set to continue with a decision for New Zealand’s Pharmaceutical…

Asia-PacificAstraZenecaFinancialHealthcareIressaOncologyPharmaceuticalRocheTarceva

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData

18-07-2013

Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

New Zealand agrees to fund Iressa but amends Tarceva use

05-07-2012

New Zealand's pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca's…

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

NZ's PHARMAC consults on funding for Iressa and Tarceva

31-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to:

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

European oncologists indicate Tarceva will threaten market position of Iressa in mutated EGFR NSCLC

02-11-2011

According to the majority of surveyed oncologists in the European Union 5 (France, Germany, Italy, Spain…

AstraZenecaEuropeIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Brazil's NSCLC cancer drug market will reach $240 million by 2014, new study shows

08-07-2010

The non-small-cell lung cancer (NSCLC) drug market in Brazil will reach a value $240 million by 2014,…

AlimtaAstraZenecaAvastinEli LillyIressaMarkets & MarketingOncologyPharmaceuticalRocheSouth AmericaTarceva

1 to 9 of 31 results

COMPANY SPOTLIGHT

Menarini

Back to top